LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Low Levels of Klothos Linked to Kidney Function Decline

By LabMedica International staff writers
Posted on 15 Feb 2017
Print article
Image: The Dade Behring BN II automated nephelometer system (Photo courtesy of Siemens Healthcare).
Image: The Dade Behring BN II automated nephelometer system (Photo courtesy of Siemens Healthcare).
The kidney has the highest levels of klotho expression and is likely the major source of soluble klotho and not surprisingly, therefore, levels of klotho tend to be low in patients with kidney disease.

Soluble klotho is a protein circulating in the blood that is thought to have anti-aging properties and although the exact mechanism of action of soluble klotho remains to be identified, the protein has been shown to influence multiple cellular and endocrine pathways.

A large team of scientists led by those at Tufts Medical Center carried out a prospective cohort initiated in 1997 with a goal of assessing how health conditions affect age-related physiologic and functional status. The study population consists of 3,075 persons aged 70 to 79 years at baseline with equal numbers of men and women and approximately one third African-Americans. All 2,496 participants who had measures of klotho and kidney function at baseline, and at least one repeat measure of kidney function were included in this study.

Serum soluble α-klotho was assayed using a commercially available sandwich enzyme-linked immunosorbent assay (ELISA) test from never-thawed frozen serum stored at -70 °C and obtained at the year two visit, approximately one year after the baseline visit. This assay is reported to have a sensitivity of 6.15 pg/mL, and demonstrated an interassay coefficient of 18%. The associations between soluble klotho levels and decline in kidney function and incident chronic kidney disease (CKD) were evaluated. Cystatin C was measured at baseline, as well as years three and 10, from stored frozen serum samples using a BNII nephelometer and an N Latex Cystatin C particle-enhanced immunonephelometric assay.

The scientists found that the median (25th, 75th percentiles) klotho level was 630 (477, 817) pg/mL. In fully adjusted models, each two-fold higher level of klotho associated with lower odds of decline in kidney function (odds ratio, 0.78) for 30% decline in estimated glomerular filtration rate (eGFR), and 0.85 for greater than 3 mL/min per year decline in eGFR, but not of incident CKD (incident rate ratio, 0.90). Overall, a higher soluble klotho level independently associated with a lower risk of decline in kidney function.

David A. Drew, MD, MS, the lead author of the study, said, “We found a strong association between low soluble klotho and decline in kidney function, independent of many known risk factors for kidney function decline. This suggests that klotho could play a role in the development of chronic kidney disease, although additional studies will need to confirm this. This also raises the possibility that klotho could be an important therapeutic target for future clinical trials.” The study was published on January 19, 2017, in the Journal of the American Society of Nephrology.

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory QC Panel
Assayed Respiratory Control Panel
New
TORCH Infections Test
TORCH Panel

Print article

Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Sekisui Diagnostics UK Ltd.